Figure 1 | Blood Cancer Journal

Figure 1

From: Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions

Figure 1

CD30 mediates its effects through a number of diverse signaling pathways, which in concert confer a survival benefit to the cells on which CD30 is upregulated. Stimulation of the CD30 molecule results in trimerization and signal mediation through tumor necrosis factor receptor-associated proteins (TRAF), in particular TRAF2, but also TRAF1 and TRAF5, to stimulate the nuclear factor-kappa B (NFkB) pathway. In addition to this, CD30 ligation also signals through the mitogen-activated protein kinase (MAPK) pathways, including ERK1 and ERK2, which have diverse anti-apoptotic and pro-survival benefits in the neoplastic cell. There appears to be a positive feedback loop between the MAPK/ERK pathway and the nuclear transcription factor JunB, which not only contributes to cell survival, but also upregulates CD30 expression.

Back to article page